---
schema_version: "secwatch.filing_event.v1"
accession: "0001600620-24-000106"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:34:35.766023+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Aurinia Q3 net product rev $55.5M (+36% YoY), net income $14.4M; restructuring cuts 45% workforce

## Summary
- Q3 total net revenue $67.8M; net product revenue $55.5M (+36% YoY); net income $14.4M vs loss of $13.4M a year ago.
- Strategic restructuring: workforce reduction ~45%, expects annual cash savings >$40M, one-time Q4 charge $15-19M.
- FY2024 net product revenue guidance reiterated $210-220M; YTD net product revenue $158.6M.
- AUR200 Phase 1 first participant dosed; initial results expected H1 2025.
- Board: Craig Johnson appointed, Dr. Robert Foster retired (not due to disagreement).

## SEC filing metadata
- accession: 0001600620-24-000106
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 2.05, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000160062024000106/0001600620-24-000106-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000160062024000106/auph-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001600620-24-000106
- JSON: https://secwatch.observer/filing/0001600620-24-000106.json
- Plain text: https://secwatch.observer/filing/0001600620-24-000106.txt

## Key facts
- Executive change
  Craig Johnson was appointed as Director at Aurinia Pharmaceuticals Inc..
  - Action: appointed
  - Role: Director
  source text: Effective November 7, 2024, Aurinia issued a press release announcing the appointment of Craig Johnson to the Board of Directors of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600620/000160062024000106/0001600620-24-000106-index.htm
- Executive change
  Scott Habig was terminated as Chief Commercial Officer at Aurinia Pharmaceuticals Inc..
  - Action: terminated
  - Role: Chief Commercial Officer
  source text: Aurinia plans to terminate its employment relationship with Scott Habig.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600620/000160062024000106/0001600620-24-000106-index.htm
- Executive change
  Dr. Robert T. Foster retired as Director at Aurinia Pharmaceuticals Inc..
  - Action: retired
  - Role: Director
  source text: the Company also announced that Dr. Robert T. Foster has retired from the Board effective November 5, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600620/000160062024000106/0001600620-24-000106-index.htm
- Restructurings & Charges
  Aurinia Pharmaceuticals Inc. announced a restructuring with charges of $15 to $19 million affecting the Company (approximately 45%).
  - Type: restructuring
  - Charge: $15 to $19 million
  - Affected area: the Company
  - Headcount: approximately 45%
  source text: cash equivalents, restricted cash, and investments of $348.7 million as of September 30, 2024 • Anticipates a one-time restructuring charge in the fourth quarter of 2024 of $15 to $19 million and estimates post-restructuring annualized cash-based operating expense savings of more than $40 million • Reiterates 2024 net product revenue guidance range of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600620/000160062024000106/0001600620-24-000106-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.